A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyPaclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyImportance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsTargeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Current targeted therapies in breast cancer: clinical applications in the elderly woman.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient PopulationHigh HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally AdvEfficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysisPredictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyOutcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumabEffectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.Primary systemic therapy in HER2-amplified breast cancer: a clinical review.Grade 3 trastuzumab-induced neutropenia in breast cancer patient.Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?HER2-Orientated Therapy in Early and Metastatic Breast Cancer.Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.An optimal stratified Simon two-stage design.Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study.Distinct tumor protein p53 mutants in breast cancer subgroups.Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers.Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Celecoxib in breast cancer prevention and therapy
P2860
Q21284978-3C6B3761-82D2-4582-9AD9-B7FA09EB31C4Q33407805-7FA2F968-2AAF-493B-9B1A-500641BB9284Q33573055-BC53486A-F6D1-4AA7-9D19-B308AA1AA53FQ33919243-E85AD59E-561D-4A79-9D6A-BFD1462E6171Q34042715-9888570E-6984-4910-80CD-D7E7FC1C92C0Q35584741-899FF3EA-B0D2-4F10-9505-83F2E33CABC3Q35687574-097C8B98-62CC-40E5-9BCD-8D779B403D3CQ36114823-41DA8627-D63C-44B1-A5FC-DD7170E929D8Q36452222-2EDC75E9-941E-4AE0-8FE6-1916DB6C3FF9Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0Q36853593-5C0CA16F-4F67-4755-8424-FDE16D0CDAD3Q36857506-DD5A0C66-8993-464C-81D5-540547862D6BQ36862845-C0126E09-9BE1-4789-81B7-ED5F1309DFE5Q36917231-E8AD14A1-F3F4-4796-A9FC-54FA794C07EDQ37709099-660E4BC6-9620-4E63-95D7-A882E2185FE3Q37872655-36B72D92-9550-4431-A6DB-D1020625FAF0Q38048814-B2CF15AD-1141-4F1E-A9AE-A10A9B3C3A8FQ38117316-C91DB0D5-534D-483F-B74E-D6AE9A6975E1Q38266772-81306371-B76D-4EF6-B14A-E121B490D64CQ38683638-0DD9D55C-5EC8-401D-97B8-ADE886F2E06BQ39147155-35C0EE0E-0EBB-4141-B9C1-E6674D26F7A0Q39410923-BFCC72D8-21FF-4B63-A454-5E8C36BE56B8Q39531178-59D80A26-9CE8-42A3-82B9-48AC08CF6030Q40877368-A996C22D-8FAD-4E79-9119-31C34ACE0325Q41094757-C4D1D182-1B12-4486-888F-53759BFF44D0Q42511112-1F627EB4-7BF9-4AE3-8F50-6DFF01111BEFQ43466172-2CAF07FE-1E8A-4B9B-AA97-7460C08CB93BQ47753755-4404E6F0-4DD6-4146-9E5C-C0FCA670DEBDQ48202060-F5BDB4C0-E865-4371-A27B-0148037F2484Q48371625-BC268E1A-3DEE-48AD-B87C-B3C736775D3CQ54242357-B975625C-7B97-49BC-8DF0-A32B0E677208Q54313406-E4C04B60-2C48-4AEA-801B-9B88DBED70B4Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30AQ57579916-C6489FE6-4148-4559-8F5A-066F52846ED4Q59135502-2770B4CB-94AE-4D82-8F95-69D01C2A94F7
P2860
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A multicenter randomized phase ...... vasive breast cancer patients.
@en
A multicenter randomized phase ...... vasive breast cancer patients.
@nl
type
label
A multicenter randomized phase ...... vasive breast cancer patients.
@en
A multicenter randomized phase ...... vasive breast cancer patients.
@nl
prefLabel
A multicenter randomized phase ...... vasive breast cancer patients.
@en
A multicenter randomized phase ...... vasive breast cancer patients.
@nl
P2093
P2860
P1476
A multicenter randomized phase ...... vasive breast cancer patients.
@en
P2093
Alexia Savignoni
Brigitte Sigal-Zafrani
Etienne Brain
Jean Marc Guinebretière
Jean-Yves Pierga
Marc Espié
Marc Spielmann
Marie-Christine Mathieu
Michel Marty
Philippe Bertheau
P2860
P2888
P304
P356
10.1007/S10549-010-0939-3
P407
P577
2010-05-18T00:00:00Z
P5875
P6179
1026380530